Transcript here
Global Health Diplomacy Commission Reports and Results from the 67th World Health Assembly Webinar, 26 May 2014 Webinar, 26 May 2014 • Series of reports timed for or around WHA 67 • Growing complexity of global health actors • Growing engagement with WHA • Close to 3500 official delegates at 67th session • Record-breaking number of agenda items, documents and resolutions • Over 20 resolutions adopted, 19 to 24 May 2014 Webinar Agenda, 26 May 2014 • Commission reports on global health diplomacy • Lancet Commission on Investing in Health • University of Oslo on Global Governance for Health • Chatham House reports on governance and financing • World Health Assembly outcomes of interest • Global governance opportunities • Health systems and surveillance issues Lancet Commission • Larry Summers and 25 global experts • Updating the message of WDR 1993 • Key messages of new report • Enormous payoffs from investing in health • Grand convergence is possible for all countries • Fiscal policies are a powerful and underutilized lever for curbing NCDs and injurites • Progressive universalism (universal health coverage) is efficient University of Oslo • The political origins of health inequity o Economic crises and austerity measures, o Knowledge and intellectual property, o Foreign investment treaties, o Food security, o Transnational corporate activity, o Irregular migration, and o Violent conflict Chatham House Reports • Governance of WHO • Functions and global role of WHO • Regional and country offices • Financing of the WHO • Sustainable health financing • Emphasis on domestic financing • Global public goods and role of external financing • Global agreement on sustainable financing Webinar Agenda, 26 May 2014 • Commission reports on global health diplomacy • Lancet Commission on Investing in Health • University of Oslo on Global Governance for Health • Chatham House reports on governance and financing • World Health Assembly outcomes of interest • Global governance opportunities • Health systems and surveillance issues WHA Global Governance Opportunities • WHO reform on nonstate actors • NCD package • Post 2015 Development Agenda • Nutrition issues WHA Global Governance Opportunities • WHO reform on nonstate actors • NCD package • Post 2015 Development Agenda • Nutrition issues WHA Global Governance Opportunities Nonstate Actors • Framework of Engagement A67/6 • Basic principles and categories of interactions • Four separate policies and operational procedures • • Requests for clarity and details on conflict of interest and financing Drafting group revised decision • 17 June follow-up questions and DG report • Regional committees separate reports • Second report from DG to Executive Board WHA Global Governance Opportunities: NCD Package • Commission on Childhood Obesity • Nine indicators for Global Action Plan • TOR for Inter-Agency Task Force • TOR for Global Coordinating Mechanism • Limited participation by non-State actors • Further work plan limits for Working Groups • UN General Assembly Summit 10 to 11 July 2014 WHA Global Governance Opportunities: Post 2015 Agenda • Expanding on MDGs for sustainable development (NCDs, mental health, newborn health, injuries) • Highest attainable standard of physical and mental health/universal health coverage • Strengthening of health systems • Health information systems • Indicators in all relevant related dimensions WHA Global Governance Opportunities: Nutrition • Maternal, infant and young child nutrition strategy • Breast milk substitutes • Inappropriate marketing of complementary foods • ICN2 – priorities to reshape the food system to respond to health needs • WHO new report on nutrition Sept 2014 Webinar Agenda, 26 May 2014 • Commission reports on global health diplomacy • Lancet Commission on Investing in Health • University of Oslo on Global Governance for Health • Chatham House reports on governance and financing • World Health Assembly outcomes of interest • Global governance opportunities • Health systems and surveillance issues Health Systems and Surveillance • Consultative Expert Working Group • Access to essential medicines • Regulatory system strengthening • Global Health Security Agenda • Antimicrobial resistance Consultative Expert Working Group • Promoting innovative components • Leishmaniasis with both DNDi and US FDA • Pathogen box for drug development – MMV • Biomarkers as diagnostics • Voluntary pooled fund through TDR • Type I access plus Types II and III diseases • Delinkage as the rallying cry Access to essential medicines • Developing a limited range of essential medicines based on best evidence • Efficient procurement • Affordable prices • Effective distribution systems • Rational use • Referral to core WHO essential medicines list Regulatory system strengthening • Supporting national regulators • Quality, safety and efficacy of products • Manufactured, stored, distributed and dispensed; • Illegal manufacturing & trade controlled & prevented; • Rational use by health professionals and public • Promotion and advertising is regulated and fair; • Access to medicines is not hindered by unjustified regulatory work.Consultative Expert Working Group Regulatory system strengthening • Strengthening of collaboration • WHO norms, standards, capacity building • Networks of strengthened regulatory authorities and • Progressive transition of prequalification Global Health Security Agenda • Launched in February 2014 • Concerns: MERS, polio, TB, influenza, antimicrobial resistance • Prevention, detection and response • Financial commitment development meeting • High-level meeting in September Global Health Security Agenda • Integrating health, security, economics, agriculture, humanitarian and diplomatic approaches • CDC working with 10 countries • Additional 30 countries to advance key milestones • $4 billion over 5 years Antimicrobial resistance • Basic priorities: • Information and extent of resistance and use in humans and animals • Increasing awareness of health providers and public • Responsible use and hand hygiene • Global action plan for WHA in 2015: • improving drug management systems, • increasing lifespan of drugs and new diagnostics and drugs Webinar, 26 May 2014 Q&A Thank You